PACIRA PHARMACEUTICALS, INC. et al v. EVENUS PHARMACEUTICALS LABORATORIES INC. et al

  1. April 08, 2025

    Pacira Reaches IP Deal Allowing Generic Painkiller In 2030

    Pacira BioSciences has agreed to settle a series of patent infringement lawsuits against Fresenius Kabi and other pharmaceutical companies over Pacira's drug Exparel, a long-acting injectable for managing postsurgical pain.

  2. August 29, 2024

    Pacira To Appeal Generic's Win In Pain Drug Patent Fight

    Pacira Pharmaceuticals Inc. says it is appealing a New Jersey federal judge's decision invalidating its patent on a nonopioid painkiller and opening the way for generic versions of its drug Exparel, a long-acting injectable for managing postsurgical pain.

  3. August 12, 2024

    Pacira Patent On Surgery Pain Drug Voided In Win For Generic

    Pacira Pharmaceuticals Inc.'s patent on a nonopioid painkiller is invalid, a New Jersey federal judge has ruled, opening the way for generic versions of Exparel, a long-acting injectable for managing postsurgical pain.

  4. May 07, 2024

    Iceberg Image Closes Pacira Drug Patent Infringement Trial

    A generic drugmaker on Tuesday used imagery to argue that the information in a Pacira Biosciences Inc. painkiller patent is just the proverbial tip of the iceberg, positing that regulators would have rejected the application if all the data on the medicine had been revealed.

  5. February 06, 2024

    Pacira Touts Stability Upgrade In Pain Drug Patent Trial

    A novel manufacturing process that extends the shelf life of the pain reliever Exparel should extend the exclusivity period of the product's patent, Pacira BioSciences Inc. has told a New Jersey judge tasked with weighing infringement claims against generic-drug maker eVenus.